{"database": "lobbying", "table": "lobbying_activities", "rows": [[1885122, "47f335c5-ea63-480c-814a-f94ade459458", "Q3", "CAPITOL HILL STRATEGIES,  LLC", 91774, "BIOGEN INC", 2016, "third_quarter", "MED", "H.R. 6, 21st Century Cures Act, (multiple provisions including incentives for innovation to help expedite novel treatments and cures, enhancements to FDA capacity and resources, and promotion of precision therapies, potential offsets)\nIssues dealing with newborn screening.\nS. 1878, Advancing Hope Act of 2015 legislation that amends the Federal Food, Drug, and Cosmetic Act to expand the priority review voucher program for rare pediatric diseases to include treatments for sickle cell disease and pediatric cancers.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2016-10-19T10:09:36.503000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1885122"], "units": {}, "query_ms": 4.680362995713949, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}